Santen Pharmaceutical Co., Ltd. (SNPHY) on Decifer

Decifer ranks SNPHY number 148 of 274 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 11% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is expected to grow about 6% a year, profits grew 17% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Solid returns around 11 percent and profits up 17 percent are steady, but expected revenue growth of 6 percent a year, no funded role, and momentum of 10 out of 35 keep it modest.

The current read

The evidence on SNPHY lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Read the full SNPHY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.